Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Success rate of developing new therapies is declining: BIO study
This is despite the fact that biotech drugs are twice as likely to gain US approval compared to traditional chemical drugs. Reportedly, the study which was conducted from
This is despite the fact that biotech drugs are twice as likely to gain US approval compared to traditional chemical drugs. Reportedly, the study which was conducted from
The idea is to work closely with external medical researchers up until the launch of a new drug which will allow GSK to tap their expertise in return
Glycosan develops, manufactures, and markets proprietary biocompatible hydrogels that mimic the extracellular matrix (ECM) that holds cells together in tissues and organs and performs many other important functions.
The study has raised researchers’ hopes of using bisphosphonates, which are indicated to stall the loss of bone mass, to help prevent cancer in healthy people, reuters.com reported.
General and administrative expenses were $1,247, 51% higher than $825,503 in the three months ended 31 December 2009. Selling expenses in the amount of $362,071 incurred during the
GeneSightRx will now measure and analyze 50 clinically important genetic variants of six genes that affect patients’ response to medications prescribed in psychiatric medicine. The enhanced six-gene Web-based
In return, Apricus Bio is entitled to receive up to a total of $4.35m in up-front, regulatory and sales milestone payments for the products. Further, over the life
In addition, OneTaq Hot Start DNA Polymerase utilizes aptamer technology; New England Biolabs ‘ unique aptamer blocks polymerase activity at temperatures below 45 degrees C, and the polymerase
Doro and MyGlucoHealth will provide a mobile solution to improve the management of diabetes. MyGlucoHealth’s testing device will integrate with some of Doro’s easy mobiles to simplify the
The single arm, open-label, Phase II study is designed to enroll patients with advanced or metastatic pancreatic adenocarcinoma with measurable disease who have not received any prior chemotherapy